Modern Inc. mRNA shares,
On hopes of accelerated development of an Omicron-specific COVID-19 booster vaccine, it gained 10.1% in premarket trading on Monday, after rising 20.7% in the previous session. Stocks of the biotechnology company fell on Friday after the company said it would “rapidly advance” a booster vaccine candidate. On Sunday, Moderna medical director Dr Paul Burton said on the BBC’s “Andrew Marr Show” that it should be known “over the next few weeks” about the ability of the current vaccine to provide protection against the Omicron variant. “If we have to make a new vaccine, I think it’s going to be early 2022, before it’s going to be available in really large quantities,” Burton said, according to bbc transcript, The stock is down 13.8% in the past three months since Friday, but is up 215.5% so far, while the S&P 500 SPX,
It has grown by 1.9% in the last three months and is up 22.3% this year.